Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: analysis of 420 surgical specimens from Japanese patients

Non-small cell lung cancer (NSCLC), accounting for approximately 85 % of all cases of lung cancer, remains the leading cause of cancer death worldwide despite the refinement of cytotoxic chemotherapies and targeted therapies. Recently, the development of immune checkpoint inhibitors, such as anti-programmed cell death-1 (PD-1) agents and anti-programmed cell death ligand-1 (PD-L1) agents, has provided a breakthrough in the treatment for NSCLC. However, their optimal utility has still been limited by the lack of definitive predictive biomarkers.

Source: Lung Cancer - October 5, 2018 Category: Cancer & Oncology Authors: Tomohito Saito, Koji Tsuta, Mitsuaki Ishida, Hironori Ryota, Yuki Takeyasu, Kento J. Fukumoto, Hiroshi Matsui, Yohei Taniguchi, Hiroaki Yanagimoto, Takayasu Kurata, Tomohiro Murakawa Source Type: research